13D Filings
Enzo Biochem, Inc.
Initial Filing
Ownership

21.80%

Total Shares

11,575,824

Issuer CIK

316253

CUSIP

294100102

Event Date

Jun 22, 2025

Accepted

Jun 30, 2025, 04:15 PM

Reporting Persons (14)
Joint Filing

This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.

NameType% of ClassAggregateSole VotingShared Voting
Battery Ventures XIV, L.P.
Partnership
21.80%11,575,824011,575,824
Battery Ventures XIV-EF, L.P.
Partnership
21.80%11,575,824011,575,824
Battery Investment Partners XIV, L.P.
Partnership
21.80%11,575,824011,575,824
Battery Partners XIV, L.P.
Partnership
21.80%11,575,824011,575,824
Battery Partners GP XIV, LLC
Other
21.80%11,575,824011,575,824
Neeraj Agrawal
Individual
21.80%11,575,824011,575,824
Michael M. Brown
Individual
21.80%11,575,824011,575,824
Morad Elhafed
Individual
21.80%11,575,824011,575,824
Jesse Feldman
Individual
21.80%11,575,824011,575,824
Russell L. Fleischer
Individual
21.80%11,575,824011,575,824
Roger H. Lee
Individual
21.80%11,575,824011,575,824
Zachary Smotherman
Individual
21.80%11,575,824011,575,824
Chelsea R. Stoner
Individual
21.80%11,575,824011,575,824
Dharmesh Thakker
Individual
21.80%11,575,824011,575,824
Disclosure Items (7)

Security Title

Common Stock, par value $0.01 per share

Issuer Name

Enzo Biochem, Inc.

Issuer Address

21 Executive Blvd., Farmingdale, NY, 11735

Filing Persons

This Schedule 13D is being filed on behalf of Battery Ventures XIV, L.P. ("BV14"), Battery Ventures XIV-EF, L.P. ("BV14-EF"), Battery Investment Partners XIV, L.P. ("BIP14"), Battery Partners XIV, L.P. ("BP14"), Battery Partners GP XIV, LLC ("BPGP14"), Neeraj Agrawal ("Agrawal"), Michael M. Brown ("Brown"), Morad Elhafed ("Elhafed"), Jesse Feldman ("Feldman"), Russel L. Fleischer ("Fleischer"), Roger H. Lee ("Lee"), Zachary Smotherman ("Smotherman"), Chelsea R. Stoner ("Stoner") and Dharmesh Thakker ("Thakker"). The foregoing individuals are collectively referred to as the "BV Managing Members" and, together with the foregoing entities, the "Reporting Persons." The Reporting Persons disclaim membership in any "group" with any person other than the Reporting Persons. The filing of this Schedule 13D by the Reporting Persons shall not be considered an admission that such Reporting Persons, for the purpose of Section 13(d) of the Exchange Act, are the beneficial owners of any of the shares of common stock covered in this report, and the Reporting Persons expressly disclaim such beneficial ownership. The agreement among the Reporting Persons to file this Schedule 13D jointly in accordance with Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended, (the "Act") is attached hereto as Exhibit 99.1.

Business Address

The principal business office of the Reporting Persons is One Marina Park Drive, Suite 1100, Boston, MA 02210.

Principal Occupation

The principal business of the Reporting Persons is venture capital investments. Agrawal, Brown, Elhafed, Feldman, Fleischer, Lee, Smotherman, Stoner and Thakker are the sole managing members of BPGP14, the general partner of BIP14 and BP14, which is the general partner of each of BV14 and BV14-EF.

Convictions

During the last five years, none of the Reporting Persons has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree of final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Citizenship

Agrawal, Brown, Feldman, Elhafed, Fleischer, Lee, Smotherman, Stoner and Thakker are citizens of the United States. BV14, BV14-EF, BIP14 and BP14 are limited partnerships organized under the laws of the State of Delaware. BPGP14 is a limited liability company organized under the laws of the State of Delaware.

Item 4 of this Schedule 13D is incorporated herein by reference.

On June 23, 2025, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Bethpage Parent, Inc., a Delaware corporation ("Bethpage"), and Bethpage Merger Sub, Inc., a New York corporation and a wholly owned subsidiary of Bethpage ("Merger Sub"). Pursuant to the terms of the Merger Agreement, Bethpage will acquire the Issuer transaction through the merger of Merger Sub with and into the Issuer, with the Issuer continuing as the surviving corporation of the merger (the "Merger") and a wholly owned subsidiary of Bethpage, subject to the terms and conditions set forth in the Merger Agreement. Bethpage and Merger Sub are each affiliates of BV14, BV14-EF and BIP 14. The foregoing description of the Merger Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Merger Agreement, a copy of which is attached hereto as Exhibit 99.2 and incorporated by reference herein. Concurrently with the execution of the Merger Agreement, all of the Company's officers and directors and the Company's largest shareholder, Harbert Discovery Fund, LP and its affiliates (collectively, the "Voting Parties") entered into voting and support agreements in favor of Bethpage and Merger Sub, pursuant to which such persons have, subject to the terms and conditions set forth therein, agreed to vote all of their shares of common stock, $0.01 par value per share, of the Issuer ("Common Stock") owned by the Voting Parties, representing approximately 21.8% of the Issuer's issued and outstanding Common Stock in the aggregate, in favor of the Merger and the adoption of the Merger Agreement and against any alternative transaction proposal (collectively, the "Voting Agreements"). In addition, each shareholder party to a Voting Agreement has agreed not to take certain actions, including (i) transferring any Shares (subject to certain exceptions), (ii) granting any proxies or powers of attorney or (iii) exercising any dissenters' rights with respect to the Merger. No separate consideration was paid by Bethpage or Merger Sub in connection with the Voting Agreement. The foregoing description of the Voting Agreements does not purport to be complete and is qualified in its entirety by reference to the full text of the Voting Agreement, a copy of which is attached hereto as Exhibit 99.3 and incorporated by reference herein.

Percentage of Class

As a result of the Voting Agreements, the Reporting Persons may be deemed to be the beneficial owner of 11,575,824 shares of the Issuer's Common Stock, which includes 656,787 shares of Common Stock issuable upon the exercise of stock options and 79,780 shares of Common Stock issuable upon the settlement of restricted stock units covered by the Voting Agreements that are either exercisable or assumed to be exercisable within 60 days of June 30, 2025. The Reporting Persons may be deemed to have the shared power to direct the vote of the shares of the Issuer's Common Stock subject to the Voting Agreements with respect to those matters described in Item 4. However, the Reporting Persons (i) are not entitled to any rights as a shareholder of the Issuer as to the shares of the Issuer's Common Stock subject to the Voting Agreements, (ii) disclaim any beneficial ownership of the shares of the Issuer's Common Stock covered by the Voting Agreements, (iii) do not have the power to dispose of the shares of the Issuer's Common Stock covered by the Voting Agreements, and (iv) do not have the power to cause the stock options to be exercised. Except as described in this Schedule 13D, none of the Reporting Persons beneficially owns any shares of the Issuer's Common Stock. BP14 is the general partner of each of BV14 and BV14-EF; BPGP14 is the general partner of each of BP14 and BIP14. The BV Managing Members are the managing members of BPGP14.

Number of Shares

Rows 7 through 10 of each Reporting Person's cover page to this Schedule 13D set forth the number of shares of Common Stock as to which such Reporting Person has the sole or shared power to vote or direct the vote and sole or shared power to dispose or to direct the disposition and are incorporated by reference.

Transactions

Except as set forth herein, none of the Reporting Persons has effected any transactions with respect to the securities of the Issuer during the past sixty days.

Shareholders

No other person is known to have the right to receive or the power to direct the receipt of dividends from, or any proceeds from the sale of, the securities beneficially owned by any of the Reporting Persons.

Date of 5% Ownership

Not applicable.

Item 4 of this Schedule 13D is incorporated herein by reference.

Exhibit 99.1 Joint Filing Agreement Exhibit 99.2 Form of Agreement and Plan of Merger, dated as of June 23, 2025 (incorporated by reference to Exhibit 2.1 to the Issuer's Current Report on Form 8-K filed with the SEC on June 24, 2025). Exhibit 99.3 Form of Voting and Support Agreement, dated as of June 23, 2025 (incorporated by reference to Exhibit 10.2 to the Issuer's Current Report on Form 8-K filed with the SEC on June 24, 2025).

Enzo Biochem, Inc. — Schedule 13D | 13D Filings